Mirabegron administration for the prevention of ureteral injuries during ureteral access sheath insertion
World Journal of Urology · 2026
DOI: 10.1007/s00345-026-06225-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Urology, 2026. Verfasst von Osman Ermiş und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Medipol Mega University Hospital, Istanbul, Turkey. Hauptthemen laut MEDLINE: Thiazoles, Ureter, Acetanilides, Adrenergic beta-3 Receptor Agonists. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Istanbul Medipol University.
Abstract (Originalsprache)
Purpose
Urolithiasis is a common condition in urological practice. Retrograde intrarenal surgery (RIRS) is widely accepted as a safe and effective treatment modality. However, acute ureteral injuries during ureteral access sheath (UAS) placement remain a significant concern. Although beta-adrenergic receptors have been identified in the ureteral wall, studies investigating beta-agonists for ureteral protection are lacking. This study aimed to assess whether short-term preoperative administration of mirabegron, a beta-3 adrenoreceptor agonist, can reduce the incidence of UAS-related ureteral injuries during RIRS.
Methods
In this prospective non-randomized study, 60 patients undergoing RIRS were enrolled. Allocation was based on clinical indications due to ethical considerations: 30 patients with existing overactive bladder symptoms received preoperative mirabegron, while 30 patients served as controls. Baseline characteristics were comparable between the groups. Ureteral injuries were assessed endoscopically and graded using the Post-Ureteroscopic Lesion Scale (PULS).
Results
The mirabegron group showed a lower incidence of high-grade ureteral injuries compared to the control group, but the difference was not statistically significant ( p = 0.123). No adverse events related to mirabegron were reported. Limitations include the lack of randomization, modest sample size, and single-center design.
Conclusions
Short-term preoperative mirabegron use appears to be safe. While our results suggest a potential trend towards reducing high-grade ureteral injuries, this did not reach statistical significance, likely due to the limited sample size of this preliminary cohort. Further large-scale, multicenter studies with longer follow-up are necessary to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Medipol Mega University Hospital, Istanbul, Turkey.
- Department of Urology, Medipol Mega University Hospital, Istanbul, Turkey. kubilay.sabuncu@medipol.edu.tr.
Förderung
- Istanbul Medipol University
Zitieren
APA
Ermiş, O., Sabuncu, K., Kaçtan, Ç., Karakuş, B., Sürmeli, B., Boz, M. Y., & Horuz, R. (2026). Mirabegron administration for the prevention of ureteral injuries during ureteral access sheath insertion. World Journal of Urology. https://doi.org/10.1007/s00345-026-06225-3
Vancouver
Ermiş O, Sabuncu K, Kaçtan Ç, Karakuş B, Sürmeli B, Boz MY, et al. Mirabegron administration for the prevention of ureteral injuries during ureteral access sheath insertion. World Journal of Urology. 2026. doi:10.1007/s00345-026-06225-3
BibTeX
@article{Ermi2026,
author = {Ermiş, Osman and Sabuncu, Kubilay and Kaçtan, Çağrı and Karakuş, Burak and Sürmeli, Bahattin and Boz, Mustafa Yücel and Horuz, Rahim},
title = {Mirabegron administration for the prevention of ureteral injuries during ureteral access sheath insertion},
journal = {World Journal of Urology},
year = {2026},
doi = {10.1007/s00345-026-06225-3}
}
EUVIMED